Benzinga | Sep 15, 2021 07:28AM EDT

BTIG Initiates Coverage On Sonnet BioTherapeutics with Buy Rating, Announces Price Target of $5

BTIG initiates coverage on Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy rating and announces Price Target of $5.